胚胎反复种植失败与淋巴细胞主动免疫的应用  

Effect of active immunotherapy with lymphocytes on repeated implantation failure

作　　者：赵芳 吕玉珍 王娟 蒋毅 田可可 

机构地区：[1]河南省焦作市妇幼保健院生殖中心,河南省焦作市454000

出　　处：《中国组织工程研究》2014年第51期8281-8285,共5页Chinese Journal of Tissue Engineering Research

摘　　要：背景:目前文献大多报道主动免疫治疗对复发性流产取得较好效果,而关于主动免疫治疗对反复种植失败的效果有待于进一步研究证实。目的:探讨封闭抗体检测和淋巴细胞主动免疫治疗在体外受精-胚胎移植反复种植失败患者中的应用。方法:对52例封闭抗体检查为阴性的反复种植失败患者,行淋巴细胞主动免疫治疗,设为观察组,74个周期,封闭抗体转阳后行胚胎移植。另选对照组65例,92个周期,直接行胚胎移植。结果与结论:反复种植失败患者行淋巴细胞主动免疫治疗后封闭抗体转阳率92%。观察组的临床妊娠率和胚胎种植率明显高于对照组(P<0.05)。两组的流产率差异无显著性意义(P>0.05)。结果表明,淋巴细胞主动免疫治疗有助于提高反复种植失败患者再次助孕的妊娠率。BACKGROUND： There are many reports addressing the good effect of active immunotherapy on repeated miscarriage, but the effect of active immunotherapy on repeated implantation failure needs to be confirmed by further studies. OBJECTIVE： To study the effect of active immunotherapy with lymphocytes on repeated implantation failure in in vitro fertilization-embryo transfer. METHODS： Active immunotherapy with lymphocytes was done in 52 repeated implantation failure patients lacking blocking antibodies. Repeated implantation failure patients were divided into two groups： study group （74 cycles）： active immunotherapy was done and blocking antibodies turned positive before embryo transfer; control group （92 cycles）： active immunotherapy was not done before embryo transfer. The pregnancy outcome was compared between two groups. RESULTS AND CONCLUSION： After the active immunotherapy with lymphocytes, the positive rate of blocking antibodies was 92% in repeated implantation failure patients. The pregnancy rate and implantation rate of study group were significantly higher than those of the control group （P 〈 0.05）, but there was no significant difference in the miscarriage rate between two groups （P 〉 0.05）. So the active immunotherapy with lymphocytes in repeated implantation failure patients may be helpful to improve the rate of pregnancy in following embryo transfer.

关 键 词：移植 抗体 妊娠 淋巴细胞 免疫系统 组织构建 体外受精-胚胎移植 反复种植失败 封闭抗体 主动免疫治疗 临床妊娠率 胚胎种植率 流产率 母胎耐受 

分 类 号：R318[医药卫生—生物医学工程]